Eugene Pietzak

9PUBLICATIONS
111CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 20, 2026
Mutational Signatures and Hypermutation Phenotypes Define Bladder Cancers Arising in Waterpipe and Cigarette Smokers.

|Oct 01, 2026
A Phase I Clinical Trial of Chemoimmunotherapy With Alternating Intravesical Gemcitabine and Bacillus Calmette-Guérin (GemBCG) for BCG-Exposed High-Grade Non-Muscle-Invasive Bladder Cancer.

|Feb 09, 2026
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.

Andrew B Katims, Charlie White, Syed Muneeb Alam

|Feb 02, 2026
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.

Brendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran

|Apr 02, 2024
Microbial cancer immunotherapy reprograms hematopoietic stem cells to enhance anti-tumor immunity.

Andrew W Daman, Anthony C Antonelli, Gil Redelman-Sidi

|Sep 08, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.

Brendan J Guercio, Michal Sarfaty, Min Yuen Teo

Pageof 2

Frequent Collaborators

7 joint publications

Hikmat Al-Ahmadie

6 joint publications

Gopa Iyer

6 joint publications

Bernard H Bochner

6 joint publications

Jonathan E Rosenberg